BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating immune-mediated disease of the central nervous system, often associated with relapses. Plasma exchange (PE) has become established as an escalation therapy for steroid-unresponsive relapses in national and international guidelines. PE is a non-selective apheresis method with elimination of the entire plasma with subsequent substitution. Selective extracorporeal elimination of autoantibodies and immune complexes with immunoadsorption (IA) is increasingly replacing PE for the treatment of autoimmune neurological diseases due to its equivalent efficacy and advantageous safety profile. The use of IA for MS still remains to become established. The aim of this retrospective investigation was to evaluate efficacy and safety of IA in patients with steroid-unresponsive relapses. PATIENTS AND METHODS: Fourteen patients with steroid-unresponsive MS relapses were retrospectively analysed. Patients received six IA treatments within 2 weeks using the single-use tryptophan adsorber. Peripheral venous access was used in 11 patients, and 3 patients needed a central line. The plasma volume treated was 2 l per IA. Efficacy criteria were improvement in symptoms of MS relapses which were measured with the Kurtzke scale (EDSS, FS) and visual acuity measurements for patients with optic neuritis. RESULTS: In 12 of 14 patients the major symptom of MS relapse improved to a clinically relevant extent after tryptophan IA; no patient got worse, corresponding to a response rate of 86%. Mean EDSS and FS in patients with spastic paresis (n=4) and dizziness (n=2) as well as mean visual acuity in patients with optic neuritis (n=8) significantly improved after IA. IA treatments were safe, with good tolerability, and no severe adverse events occurred. CONCLUSION: Immunoadsorption for the treatment of steroid-unresponsive MS relapses was safe and effective. The response rate was comparable to published results with PE. With IA, in contrast to unselective PE, administration of human plasma products is not necessary, avoiding associated risks.
BACKGROUND:Multiple sclerosis (MS) is a chronic inflammatory demyelinating immune-mediated disease of the central nervous system, often associated with relapses. Plasma exchange (PE) has become established as an escalation therapy for steroid-unresponsive relapses in national and international guidelines. PE is a non-selective apheresis method with elimination of the entire plasma with subsequent substitution. Selective extracorporeal elimination of autoantibodies and immune complexes with immunoadsorption (IA) is increasingly replacing PE for the treatment of autoimmune neurological diseases due to its equivalent efficacy and advantageous safety profile. The use of IA for MS still remains to become established. The aim of this retrospective investigation was to evaluate efficacy and safety of IA in patients with steroid-unresponsive relapses. PATIENTS AND METHODS: Fourteen patients with steroid-unresponsive MS relapses were retrospectively analysed. Patients received six IA treatments within 2 weeks using the single-use tryptophan adsorber. Peripheral venous access was used in 11 patients, and 3 patients needed a central line. The plasma volume treated was 2 l per IA. Efficacy criteria were improvement in symptoms of MS relapses which were measured with the Kurtzke scale (EDSS, FS) and visual acuity measurements for patients with optic neuritis. RESULTS: In 12 of 14 patients the major symptom of MS relapse improved to a clinically relevant extent after tryptophan IA; no patient got worse, corresponding to a response rate of 86%. Mean EDSS and FS in patients with spastic paresis (n=4) and dizziness (n=2) as well as mean visual acuity in patients with optic neuritis (n=8) significantly improved after IA. IA treatments were safe, with good tolerability, and no severe adverse events occurred. CONCLUSION: Immunoadsorption for the treatment of steroid-unresponsive MS relapses was safe and effective. The response rate was comparable to published results with PE. With IA, in contrast to unselective PE, administration of human plasma products is not necessary, avoiding associated risks.
Authors: S Schilling; R A Linker; F B König; M Koziolek; M Bähr; G A Müller; W Paulus; J Gärtner; W Brück; A Chan; R Gold Journal: Nervenarzt Date: 2006-04 Impact factor: 1.214
Authors: B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez Journal: Ann Neurol Date: 1999-12 Impact factor: 10.422
Authors: Jana-Maria Schneidewind-Müller; Roland E Winkler; Michael Tiess; Waltraud Müller; Wolfgang Ramlow Journal: Artif Organs Date: 2002-02 Impact factor: 3.094
Authors: A Moldenhauer; J Haas; C Wäscher; T Derfuss; K-T Hoffmann; H Kiesewetter; A Salama Journal: Eur J Clin Invest Date: 2005-08 Impact factor: 4.686
Authors: D Grob; D Simpson; H Mitsumoto; B Hoch; F Mokhtarian; A Bender; M Greenberg; A Koo; S Nakayama Journal: Neurology Date: 1995-02 Impact factor: 9.910
Authors: F Hoffmann; A Kraft; F Heigl; E Mauch; J Koehler; L Harms; T Kümpfel; W Köhler; R Klingel; C Fassbender; S Schimrigk Journal: Nervenarzt Date: 2015-02 Impact factor: 1.214
Authors: S Ehrlich; C M Fassbender; C Blaes; C Finke; A Günther; L Harms; F Hoffmann; K Jahner; R Klingel; A Kraft; T Lempert; M Tesch; J Thomsen; H Topka; J Jochim; C Veauthier; W Köhler Journal: Nervenarzt Date: 2013-04 Impact factor: 1.214
Authors: Leoni Rolfes; Steffen Pfeuffer; Tobias Ruck; Nico Melzer; Marc Pawlitzki; Michael Heming; Marcus Brand; Heinz Wiendl; Sven G Meuth Journal: J Clin Med Date: 2019-10-04 Impact factor: 4.241
Authors: Tobias Moser; Gayane Harutyunyan; Anush Karamyan; Ferdinand Otto; Carola Bacher; Vaclav Chroust; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner Journal: Brain Sci Date: 2019-10-09
Authors: Steffen Pfeuffer; Leoni Rolfes; Heinz Wiendl; Sven G Meuth; Timo Wirth; Falk Steffen; Marc Pawlitzki; Andreas Schulte-Mecklenbeck; Catharina C Gross; Marcus Brand; Stefan Bittner; Tobias Ruck; Luisa Klotz Journal: J Neuroinflammation Date: 2022-09-07 Impact factor: 9.587
Authors: Georgina Arrambide; Ellen Iacobaeus; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Lou Brundin; Mar Tintore Journal: Mult Scler Date: 2020-06-12 Impact factor: 6.312